In the competitive landscape of biotechnology, Alnylam Pharmaceuticals and Incyte Corporation present intriguing investment opportunities.
When evaluating stocks in the biotechnology sector, investors often look for value indicators such as price-to-earnings (P/E), price-to-earnings growth (PEG), and price-to-book (P/B) ratios. In this comparison, we will explore Alnylam Pharmaceuticals Inc (ALNY) and Incyte Corporation (INCY) to determine which stock appears to offer better value based on these metrics.
Investor takeaway: While Incyte Corporation screens cheaper on several key multiples, it is essential to consider that lower valuations do not inherently indicate a superior investment. Each company has its own unique growth prospects and risks.
Advertisement
Stocks in this list
Live snapshots — open any name for the full quote and Wealth Awesome price forecast.
Alnylam Pharmaceuticals Inc
ALNY.US
Health Care
$224.41
$29.97B
1D
+0.21%
1W
-9.05%
Incyte Corporation
INCY.US
Health Care
$113.44
$22.85B
1D
+0.63%
1W
-6.52%
Advertisement
Valuation Comparison
Incyte Corporation shows a more attractive valuation with a P/E of 14.4, compared to Alnylam's 37.8, and a P/B of 3.59 versus Alnylam's 22.16.
Advertisement
Bull case
Incyte Corporation's lower P/E of 14.4 compared to Alnylam's 37.8 suggests it offers a more appealing valuation relative to earnings. With a PEG ratio of 10.82, it may be viewed as a more stable growth option, even though it comes at a higher cost relative to its earnings growth. Investors might appreciate the solid return on equity (ROE) of 30.7%, indicating effective management of equity.
Bear case
On the other hand, Alnylam Pharmaceuticals boasts an impressive ROE of 96.6%, showcasing exceptional profitability and management efficiency. However, its high P/E of 37.8 and PEG of 0.32 could imply that the market has lofty expectations for its future growth, which may be challenging to fulfill. This significant premium in valuation might deter some value-focused investors.
Analyst Consensus and Targets
Both companies have received a 'Buy' consensus from analysts, indicating positive sentiment towards their future performance. The analyst target for Alnylam Pharmaceuticals is US$371.12, while Incyte Corporation's target is US$128.92. These targets reflect the potential upside perceived by analysts, but they also highlight the differing growth expectations between the two companies.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
